128 related articles for article (PubMed ID: 15244255)
1. Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma.
Osby E; Askling J; Landgren O; Dickman PW; Ekbom A; Björkholm M
Acta Oncol; 2004; 43(3):297-301. PubMed ID: 15244255
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
[TBL] [Abstract][Full Text] [Related]
3. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
[TBL] [Abstract][Full Text] [Related]
4. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
5. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.
Pangalis GA; Vassilakopoulos TP; Michalis E; Roussou P; Vrakidou E; Repousis P; Angelopoulou MK; Siakantaris MP; Korantzis J; Symeonidis A; Grigorakis V; Stefanoudakis E; Stamatellou M; Bourantas KL; Kalmantis T; Christopoulos G; Kokkinis G; Mihalakeas I; Papayiannis A;
Leuk Lymphoma; 2003 Apr; 44(4):635-44. PubMed ID: 12769340
[TBL] [Abstract][Full Text] [Related]
7. Parental longevity and survival in elderly patients with Hodgkin's lymphoma.
Landgren O; Askling J; Dickman PW; Osby E; Axdorph U; Ekbom A; Björkholm M
Haematologica; 2002 Jun; 87(6):596-601. PubMed ID: 12031915
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
Gómez H; Hidalgo M; Casanova L; Colomer R; Pen DL; Otero J; Rodríguez W; Carracedo C; Cortés-Funes H; Vallejos C
J Clin Oncol; 1998 Jun; 16(6):2065-9. PubMed ID: 9626205
[TBL] [Abstract][Full Text] [Related]
9. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
Osby E; Hagberg H; Kvaløy S; Teerenhovi L; Anderson H; Cavallin-Stahl E; Holte H; Myhre J; Pertovaara H; Björkholm M;
Blood; 2003 May; 101(10):3840-8. PubMed ID: 12531794
[TBL] [Abstract][Full Text] [Related]
10. [Survival of patients with aggressive non-hodgkin's lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice].
van Agthoven M; Wittebol S; Budel LM; Uyl-de Groot CA; Kramer MH
Ned Tijdschr Geneeskd; 2004 Jan; 148(2):88-93. PubMed ID: 14753131
[TBL] [Abstract][Full Text] [Related]
11. CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience.
Vose JM; Weisenburger DD; Lynch JC; Bierman PJ; Chan JC; Bast M; Aoun P; Bociek G; Greiner T; Armitage JO;
Leuk Lymphoma; 2002 Apr; 43(4):799-804. PubMed ID: 12153167
[TBL] [Abstract][Full Text] [Related]
12. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.
Peters FP; Lalisang RI; Fickers MM; Erdkamp FL; Wils JA; Houben SG; Wals J; Schouten HC
Ann Hematol; 2001 Mar; 80(3):155-9. PubMed ID: 11320900
[TBL] [Abstract][Full Text] [Related]
13. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
[TBL] [Abstract][Full Text] [Related]
14. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
Sharma R; Cunningham D; Smith P; Robertson G; Dent O; Clarke SJ
BMC Cancer; 2009 May; 9():153. PubMed ID: 19450285
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
[TBL] [Abstract][Full Text] [Related]
17. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Alliot C
J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
[No Abstract] [Full Text] [Related]
18. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
19. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
[TBL] [Abstract][Full Text] [Related]
20. Overview of rational and individualized therapeutic strategies for non-Hodgkin's lymphomas.
Armitage JO
Clin Lymphoma; 2002 Dec; 3 Suppl 1():S5-11. PubMed ID: 12521383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]